Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy

Journal of Surgical Oncology

Volumn 98, Issue 2, 2008, Pages 130-134

  Grau, Juan J ^a   Caballero, Miguel ^a,b   Monzó, Mariano ^a   Muñoz García, Carmen ^a   Domingo Domenech, Jose ^a   Navarro, Alfons ^a   Conill, Carlos ^a   Campayo, Marc ^a   Bombí, Jose A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Cytidine deaminase; Dihydropyrimidine dehydrogenases; Gastric cancer; Polymorphisms; Tegafur

Indexed keywords

ARGININE; CDA PROTEIN; CYANOCOBALAMIN; CYTIDINE DEAMINASE; DIHYDROPYRIMIDINE DEHYDROGENASE; DPYD1 PROTEIN; DPYD2 PROTEIN; FLUOROURACIL; ISOLEUCINE; LYSINE; MITOMYCIN C; PHOSPHOPROTEIN; TEGAFUR; VALINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CYANOCOBALAMIN DEFICIENCY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GASTRECTOMY; GENE FREQUENCY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; STOMACH ADENOCARCINOMA; TOXICITY; WILD TYPE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; CYTIDINE DEAMINASE; DIHYDROURACIL DEHYDROGENASE (NADP); DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GENE FREQUENCY; GENOTYPE; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS; TEGAFUR;

EID: 49049153075     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21096     Document Type: Article

References (19)

1. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
2. Cunningham D, Allum WH, Stenning SP, et al.: MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
3. Grau JJ, Estape J, Fuster J, et al.: Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol 1998;16:1036-1039.
4. Kohne CH, Folprecht G: Current perspectives in the treatment of metastatic colorectal cancer. Ann Oncol 2004;15:43-53.
5. van Kuilenburg AB: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-flurorouracil. Eur J Cancer 2004;40:939-950.
6. Jackson RC: The regulation of thymidylate biosynthesis in Novikoff hepatoma cells and the effects of amethopterin, 5-fluorodeoxyuridine, and 3-deazauridine. J Biol Chem 1978;253:7440-7446.
7. Somasekaram A, Jarmuz A, How A, et al.: Intracellular localization of human cytidine deaminase. J Biol Chem 1999;274:28405-28412.
8. Fischel JL, Etienne MC, Spector T, et al.: Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation. Clin Cancer Res 1995;1:991-996.
9. Ho DH, Townsend L, Luna MA, et al.: Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986;6:781-784.
10. Ichikawa W, Uetake H, Shirota Y, et al.: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786-791.
11. Higashiyama M, Kodama K, Yokouchi H, et al.: Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: Relationship with in vitro sensitivity to 5-fluorouracil. Lung Cancer 2001;34:407-416.
12. Nakagawa T, Tanaka F, Takata T, et al.: Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur+Uracil) in patients with p-stage I nonsmall-cell lung cancer. J Surg Oncol 2002;81:87-92.
13. Ichikawa W, Uetake H, Shirota Y, et al.: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786-791.
14. Horiguchi J, Yoshida T, Koibuchi Y, et al.: DPD activity and immunohistochemical DPD expression in human breast cancer. Oncol Rep 2004;11:65-72.
15. Efferth T, Volm M: Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005:155-176.
16. Epeldegui M, Widney DP, Martinez-Maza O: Pathogenesis of AIDS lymphoma: Role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 2006;18:444-448.
17. Marsh S, McLeod HL: Cancer pharmacogenetics. Br J Cancer 2004;90:8-11.
18. Watanabe S, Uchida T: Expression of cytidine deaminase in human solid tumors and its regulation by 1 alpha,25-dihydroxyvitaminD3. Biochim Biophys Acta 1996;1312:99-104.
19. Matsumoto Y, Marusawa H, Kinoshita K, et al.: Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007:13:470-476.